Allogene Therapeutics, Inc. Increase (Decrease) in Contract with Customer, Liability
Allogene Therapeutics, Inc. (ALLO) reported Increase (Decrease) in Contract with Customer, Liability of $0 for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-13.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2024-05-13
- Allogene Therapeutics, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2024-03-31 was $0.00.
- Allogene Therapeutics, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2023-12-31 was $0.00.
- Allogene Therapeutics, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2023-09-30 was $0.00.
- Allogene Therapeutics, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2023-06-30 was $0.00.
- Allogene Therapeutics, Inc. increase (decrease) in contract with customer, liability for fiscal 2023 was -$3.00K.
- Allogene Therapeutics, Inc. increase (decrease) in contract with customer, liability for fiscal 2022 was -$21.00K.
- Allogene Therapeutics, Inc. increase (decrease) in contract with customer, liability for fiscal 2021 was -$38.30M, a 199.86% decline from fiscal 2020.
- Allogene Therapeutics, Inc. increase (decrease) in contract with customer, liability for fiscal 2020 was $38.35M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 3 month as first filed | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 6 month as first filed | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 9 month as first filed | Increase (Decrease) in Contract with Customer, Liability 12 month | Increase (Decrease) in Contract with Customer, Liability 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | $0.00 10-Q · filed 2024-05-13 | $0.00 derived: sum of 2 quarters · filed 2024-05-13 | $0.00 derived: sum of 3 quarters · filed 2024-05-13 | $0.00 derived: sum of 4 quarters · filed 2024-05-13 | ||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-K 9 month · filed 2024-03-14 | $0.00 derived: sum of 2 quarters · filed 2024-03-14 | $0.00 derived: sum of 3 quarters · filed 2024-03-14 | -$3.00K 10-K · filed 2024-03-14 | ||||
| 2023-09-30 | $0.00 derived: 10-K 9 month − 10-K 6 month · filed 2024-03-14 | $0.00 derived: sum of 2 quarters · filed 2024-03-14 | -$3.00K 10-K · filed 2024-03-14 | -$649.00K 10-Q · filed 2023-11-02 | -$5.00K derived: sum of 4 quarters · filed 2024-05-13 | |||
| 2023-06-30 | $0.00 derived: 10-K 6 month − 10-Q 3 month · filed 2024-03-14 | -$3.00K 10-K · filed 2024-03-14 | -$656.00K 10-Q · filed 2023-08-02 | -$5.00K derived: sum of 3 quarters · filed 2024-05-13 | -$7.00K derived: sum of 4 quarters · filed 2024-05-13 | |||
| 2023-03-31 | -$3.00K 10-Q · filed 2024-05-13 | -$612.00K 10-Q · filed 2023-05-03 | -$5.00K derived: sum of 2 quarters · filed 2024-05-13 | -$7.00K derived: sum of 3 quarters · filed 2024-05-13 | -$21.00K derived: sum of 4 quarters · filed 2024-05-13 | |||
| 2022-12-31 | -$2.00K derived: 10-K/A 12 month − 10-K 9 month · filed 2024-03-14 | -$4.00K derived: sum of 2 quarters · filed 2024-03-14 | -$18.00K derived: sum of 3 quarters · filed 2024-03-14 | -$21.00K 10-K/A · filed 2024-03-14 | $462.00K 10-K · filed 2023-02-28 | |||
| 2022-09-30 | -$2.00K derived: 10-K 9 month − 10-K 6 month · filed 2024-03-14 | -$16.00K derived: sum of 2 quarters · filed 2024-03-14 | -$19.00K 10-K · filed 2024-03-14 | $466.00K 10-Q · filed 2022-11-02 | $311.00K derived: sum of 4 quarters · filed 2024-03-14 | |||
| 2022-06-30 | -$14.00K derived: 10-K 6 month − 10-K 3 month · filed 2024-03-14 | -$17.00K 10-K · filed 2024-03-14 | $413.00K 10-Q · filed 2022-08-09 | $313.00K derived: sum of 3 quarters · filed 2024-03-14 | $373.00K derived: sum of 4 quarters · filed 2024-03-14 | |||
| 2022-03-31 | -$3.00K 10-K · filed 2024-03-14 | -$17.00K 10-Q · filed 2022-05-04 | $327.00K derived: sum of 2 quarters · filed 2024-03-14 | $387.00K derived: sum of 3 quarters · filed 2024-03-14 | $453.00K derived: sum of 4 quarters · filed 2024-03-14 | |||
| 2021-12-31 | $330.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $390.00K derived: sum of 2 quarters · filed 2024-03-14 | $456.00K derived: sum of 3 quarters · filed 2024-03-14 | -$38.30M 10-K/A · filed 2024-03-14 | -$38.57M 10-K · filed 2022-02-23 | |||
| 2021-09-30 | $60.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $126.00K derived: sum of 2 quarters · filed 2022-11-02 | -$38.63M 10-Q · filed 2022-11-02 | -$278.00K derived: sum of 4 quarters · filed 2024-03-14 | ||||
| 2021-06-30 | $66.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$38.69M 10-Q · filed 2022-08-09 | -$338.00K derived: sum of 3 quarters · filed 2024-03-14 | -$338.00K derived: sum of 4 quarters · filed 2024-03-14 | ||||
| 2021-03-31 | -$38.75M 10-Q · filed 2022-05-04 | -$404.00K derived: sum of 2 quarters · filed 2024-03-14 | -$404.00K derived: sum of 3 quarters · filed 2024-03-14 | -$404.00K derived: sum of 4 quarters · filed 2024-03-14 | ||||
| 2020-12-31 | $38.35M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $38.35M derived: sum of 2 quarters · filed 2024-03-14 | $38.35M derived: sum of 3 quarters · filed 2024-03-14 | $38.35M 10-K/A · filed 2024-03-14 | $38.99M 10-K · filed 2021-02-25 | |||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $0.00 derived: sum of 2 quarters · filed 2021-11-04 | $0.00 10-Q · filed 2021-11-04 | |||||
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $0.00 10-Q · filed 2021-08-04 | ||||||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-05 | |||||||
| 2019-12-31 | $0.00 10-K · filed 2022-02-23 | |||||||
| 2018-12-31 | $0.00 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |